Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General Hospital

Antoni Llueca, José Luis Herráiz, Carmen Catalá, Anna Serra, Isabel Rivadulla, Javier Escrig‐Sos, MUAPOS Working Group

Journal of Clinical Gynecology and Obstetrics · 2015 · 14 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Background: The aim of the study was to evaluate the initial efficiency
\nand security of maximal effort cytoreductive surgery in stages
\nIII and IV of ovarian cancer at a university hospital.
\nMethods: Thirty-four patients with stage III and IV ovarian carcinoma
\nunderwent surgery between January 2013 and June 2014 in
\nthe University General Hospital of Castellon (Spain). Patients with
\nprimary and relapse ovarian cancer were included. The extent of disease,
\ntype of surgical technique, amount of tumor prior to surgery and
\namount of residual disease after surgery were recorded. To quantify
\nthe efficiency and the security of the procedure, the complete cytoreduction
\nand the morbidity and the mortality rates were described.
\nResults: Of the patients 26.4% received neoadjuvant chemotherapy.
\nComplete cytoreductive surgery, without evident residual tumor at the
\nend of the procedure, was obtained in 79% of patients and optimal cytoreductive
\nsurgery (CC0-CC1) in 91%. Surgical complications were
\nfound in 56% of patients and two deaths (6%) occurred attributable to
\nsurgery. The disease free interval was 15 months.
\nConclusions: This study confirms that with experienced multidisciplinary
\nteams and in tertiary referral hospitals, 79% of complete
\ncytoreduction surgery in advanced ovarian cancer can be achieved
\nbut they must be prepared to deal with a high rate of complications

References

10